Prognostic Value of a 25-Gene Assay in Patients with Gastric Cancer after Curative Resection

Xiaohong Wang,Yiqiang Liu,Zhaojian Niu,Runjia Fu,Yongning Jia,Li Zhang,Duanfang Shao,Hong Du,Ying Hu,Xiaofang Xing,Xiaojing Cheng,Lin Li,Ting Guo,Ziyu Li,Qunsheng Ji,Lianhai Zhang,Jiafu Ji
DOI: https://doi.org/10.1038/s41598-017-07604-y
IF: 13.576
2016-01-01
Clinical Gastroenterology and Hepatology
Abstract:This study aimed to develop and validate a practical, reliable assay for prognosis and chemotherapy benefit prediction compared with conventional staging in Gastric cancer (GC). Twenty-three candidate genes with significant correlation between quantitative hybridization and microarray results plus 2 reference genes were selected to form a 25-gene prognostic classifier, which can classify patients into 3 distinct groups of different risk of mortality obtained by analyzing microarray data from 78 frozen tumor specimens. The 25-gene assay was associated with overall survival in both training ( P = 0.017) and testing cohort ( P = 0.005) (462 formalin-fixed paraffin-embedded samples). The risk prediction in stages I + II is significantly better than that in stages III. Analysis demonstrated that this 25-gene signature is an independent prognostic predictor and show higher prognostic accuracy than conventional TNM staging in early stage patients. Moreover, only high-risk patients in stage I + II were found benefit from adjuvant chemotherapy ( P = 0.043), while low-risk patients in stage III were not found benefit from adjuvant chemotherapy. In conclusion, our results suggest that this 25-gene assay can reliably identify patients with different risk for mortality after surgery, especially for stage I + II patients, and might be able to predict patients who benefit from chemotherapy.
What problem does this paper attempt to address?